GSK to discontinue the manufacture and supply of Zantac products

MG News | May 19, 2020 at 11:31 AM GMT+05:00

0:00

May 18, 2020 (MLN): GlaxoSmithKline has decided to discontinue the manufacture and supply of the Ranitidine brand (Zantac).

Last year, the company was contacted by regulatory authorities regarding the detection of NDMA in Zantac (Ranitidine) products. Based on the information received and correspondence with regulatory authorities, GSK made the decision in September 2019 and extended it in October 2019, to initiate a voluntary pharmacy/retail level recall in all markets of Zantac products manufactured using all API sources, as a precautionary action.

The recall also applied to all Zantac products manufactured in Pakistan. GSK continued to respond to the queries received from the regulatory authorities and to work actively with them to address their concerns. It also conducted investigations into the potential source of the NDMA.

With the discontinuation of Zantac’s manufacture, the company has informed that there are alternatives medicines to Ranitidine available, as noted by the European Medicines Agency (EMA).

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	152,740.38 147.44M	-1.01% -1551.88
ALLSHR	91,858.47 324.25M	-0.86% -800.10
KSE30	46,223.61 86.89M	-1.45% -681.25
KMI30	219,130.92 66.08M	-1.15% -2553.50
KMIALLSHR	59,625.28 139.61M	-0.93% -562.17
BKTi	42,104.46 39.09M	-2.02% -866.56
OGTi	32,077.87 10.13M	-1.27% -414.19

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	70,655.00	70,980.00 70,425.00	-80.00 -0.11%
BRENT CRUDE	100.06	114.43 96.00	-12.13 -10.81%
RICHARDS BAY COAL MONTHLY	99.40	0.00 0.00	-11.50 -10.37%
ROTTERDAM COAL MONTHLY	123.30	123.30 123.30	1.70 1.40%
USD RBD PALM OLEIN	1,083.50	1,083.50 1,083.50	0.00 0.00%
CRUDE OIL - WTI	88.70	89.50 88.50	0.57 0.65%
SUGAR #11 WORLD	15.52	15.75 15.38	-0.18 -1.15%